In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...
Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...
Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...
NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis of the condition in primary care, an expert report has said. The Alliance ...
Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results